A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers

Advanced Solid Cancers Clinical Trial

Official title:
A Phase I Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane (Paclitaxel Protein-bound Particles) in Advanced Solid Cancers

Status Terminated

Clinical Trial Summary

Rapamycin is a drug that has been approved by the Food and Drug Administration (government) for use in patients receiving a kidney transplant to prevent the patient's body from rejecting the transplanted kidney. It has shown antitumor effects in the laboratory, but has not been approved at this time for the treatment of cancer. Abraxane is a new form of chemotherapy that has been approved by the Food and Drug Administration for the treatment of metastatic breast cancer, and is a promising drug that is being evaluated in clinical trials for treatment of other cancers. This is a phase I study designed to find out if different doses of Rapamycin, when combined with Abraxane, are safe and well tolerated.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Advanced Solid Cancers

Clinical Trial Details

NCT number	NCT00337376
Study type	Interventional
Source	Yale University
Contact
Status	Terminated
Phase	Phase 1
Start date	February 2006
Completion date	July 2010

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT02792465` - A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors	Phase 1
Terminated	`NCT00886782` - A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors	Phase 1/Phase 2
Completed	`NCT03956680` - An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers	Phase 1
Completed	`NCT03512340` - Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers	Phase 1
Terminated	`NCT03254732` - Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers	Phase 1
Completed	`NCT00478101` - Opioid Rotation Versus Combination for Chronic Uncontrolled Cancer Pain	Phase 2
Completed	`NCT01019941` - Pharmacokinetic Study of CKD-810 and Taxotere to Treat Patient With Advanced Solid Cancer	Phase 1
Completed	`NCT02694822` - AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Subjects With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy	Phase 1/Phase 2